Your browser doesn't support javascript.
loading
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
Rocca, Andrea; Cortesi, Pietro; Cortesi, Laura; Gianni, Lorenzo; Matteucci, Federica; Fantini, Lorenzo; Maestri, Antonio; Giunchi, Donata Casadei; Cavanna, Luigi; Ciani, Rosa; Falcini, Fabio; Bagni, Antonella; Meldoli, Elena; Dall'Agata, Monia; Volpi, Roberta; Andreis, Daniele; Nanni, Oriana; Curcio, Annalisa; Lucchi, Leonardo; Amadori, Dino; Fedeli, Anna.
Afiliação
  • Rocca A; Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, Meldola 47014, Italy.
  • Cortesi P; Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Cortesi L; Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Gianni L; Department of Medical Oncology, Infermi Hospital, Rimini, Italy.
  • Matteucci F; Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Fantini L; Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Maestri A; Department of Medical Oncology, Santa Maria della Scaletta Hospital, Imola, Italy.
  • Giunchi DC; Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Cavanna L; Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy.
  • Ciani R; Cancer Prevention Unit, Azienda Usl della Romagna, Forlì, Italy.
  • Falcini F; Cancer Prevention Unit, Azienda Usl della Romagna, Forlì, Italy Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Bagni A; Breast Diagnostic Unit, Maurizio Bufalini Hospital, Cesena, Italy.
  • Meldoli E; Breast Diagnostic Unit, Maurizio Bufalini Hospital, Cesena, Italy.
  • Dall'Agata M; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Volpi R; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Andreis D; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Nanni O; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Curcio A; Breast Surgery Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.
  • Lucchi L; Breast Surgery Unit, Maurizio Bufalini Hospital, Forlì, Italy.
  • Amadori D; Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Fedeli A; Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Ther Adv Med Oncol ; 13: 1758835920985632, 2021.
Article em En | MEDLINE | ID: mdl-33613693
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article